Literature DB >> 10845659

Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases.

C Roozendaal1, M A de Jong, A P van den Berg, R T van Wijk, P C Limburg, C G Kallenberg.   

Abstract

BACKGROUND/AIMS: The clinical relevance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver disease is unclear. Defining the antigenic specificities of ANCA in these diseases may improve their clinical significance.
METHODS: We studied the target antigens of ANCA in 88 patients with autoimmune hepatitis, 53 patients with primary biliary cirrhosis, and 55 patients with primary sclerosing cholangitis by indirect immunofluorescence, antigen-specific enzyme-linked immunosorbent assays, and immunodetection on Western blot, using an extract of whole neutrophils as a substrate. We related the data to clinical symptoms of autoimmune liver disease.
RESULTS: By indirect immunofluorescence, ANCA were present in 74% of patients with autoimmune hepatitis, 26% of patients with primary biliary cirrhosis, and 60% of patients with primary sclerosing cholangitis. Major antigens were catalase, alpha-enolase, and lactoferrin. The presence of ANCA as detected by indirect immunofluorescence was associated with the occurrence of relapses in autoimmune hepatitis, with decreased liver synthesis function in primary biliary cirrhosis and in primary sclerosing cholangitis, and with increased cholestasis in primary sclerosing cholangitis. ANCA of defined specificities had only limited clinical relevance.
CONCLUSIONS: ANCA as detected by indirect immunofluorescence seem associated with a more severe course of autoimmune liver disease. The target antigens for ANCA in these diseases include catalase, alpha-enolase, and lactoferrin. Assessment of the antigenic specificities of ANCA in autoimmune liver disease does not significantly contribute to their clinical significance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845659     DOI: 10.1016/s0168-8278(00)80241-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  25 in total

1.  IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 2.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 3.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

Review 4.  Biliary atresia: cellular dynamics and immune dysregulation.

Authors:  Amy G Feldman; Cara L Mack
Journal:  Semin Pediatr Surg       Date:  2012-08       Impact factor: 2.754

Review 5.  Membranous nephropathy: the start of a paradigm shift.

Authors:  Sandra M S Herrmann; Sanjeev Sethi; Fernando C Fervenza
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-03       Impact factor: 2.894

Review 6.  Autoimmune hepatitis in childhood: the role of genetic and immune factors.

Authors:  Priscila Menezes Ferri Liu; Débora Marques de Miranda; Eleonora Druve Tavares Fagundes; Alexandre Rodrigues Ferreira; Ana Cristina Simões e Silva
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

7.  α-enolase autoantibodies cross-reactive to viral proteins in a mouse model of biliary atresia.

Authors:  Brandy R Lu; Stephen M Brindley; Rebecca M Tucker; Cherie L Lambert; Cara L Mack
Journal:  Gastroenterology       Date:  2010-07-23       Impact factor: 22.682

8.  Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.

Authors:  Ye H Oo; Stefan G Hubscher; David H Adams
Journal:  Hepatol Int       Date:  2010-05-19       Impact factor: 6.047

9.  Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study.

Authors:  Nikolaos K Gatselis; Sarah P Georgiadou; Nikolaos Tassopoulos; Kalliopi Zachou; Christos Liaskos; Angelos Hatzakis; Georgios N Dalekos
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

10.  Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.

Authors:  Hind I Fallatah; Hisham O Akbar
Journal:  Autoimmune Dis       Date:  2012-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.